Combining anti-TIGIT and anti-PD-1 antibodies for glioblastoma
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
This offers people with glioblastoma a short, early test of two immune drugs—an anti-TIGIT antibody plus an anti-PD-1 antibody—to try to restore their T cells' ability to fight the tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11252782 on NIH RePORTER |
What this research studies
You would receive a short, early-stage course of two immune antibodies (anti-TIGIT AB154 and anti-PD-1 AB122) given by your cancer team. Doctors will monitor safety, side effects, and changes in immune cells using blood and tumor samples, including detailed lab tests like single-cell RNA sequencing. The study may require surgery or a biopsy to collect tumor tissue and regular clinic visits for monitoring. This Phase 0/1 effort focuses on safety and immune effects rather than proving long-term benefit.
Who could benefit from this research
Good fit: Adults (age 21+) with glioblastoma who meet the trial's medical and surgical criteria and can provide tumor and blood samples are the intended candidates.
Not a fit: People with non-glioblastoma brain tumors, those too frail for immunotherapy or surgery, or those unwilling/unable to provide tumor samples are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, this approach could revive anti-tumor T cell activity and improve how glioblastoma responds to immunotherapy.
How similar studies have performed: Anti-TIGIT antibodies have shown promise in other cancers (one agent received FDA breakthrough designation), but PD-1 drugs alone have not worked well in glioblastoma, so this combination is relatively new.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Hafler, David a. — Yale University
- Study coordinator: Hafler, David a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.